Tech Company Financing Transactions
ACT Biotech Funding Round
On 5/8/2008, ACT Biotech raised $12 million in Series A funding from NGN Capital.
Transaction Overview
Company Name
Announced On
5/8/2008
Transaction Type
Venture Equity
Amount
$12,000,000
Round
Series A
Investors
NGN Capital (Lead Investor) (Georg Nebgen)
Proceeds Purpose
Under the terms of the license agreement with Bayer, ACT Biotech hasacquired an anti-angiogenic receptor tyrosine kinase inhibitor enteringPhase II clinical studies for colorectal cancer, amongst other indications.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
717 Market St.
San Francisco, CA 94103
USA
San Francisco, CA 94103
USA
Phone
Undisclosed
Website
Email Address
Overview
ACT Biotech is a biopharmaceutical company focused on the development and commercialization of cancer drugs.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Bernard Peperstraete
Browse more venture capital transactions:
Prev: 5/8/2008: OrthoHelix Surgical Designs venture capital transaction
Next: 5/8/2008: Intrexon venture capital transaction
Share this article
About Database of VC Transactions
Our team works diligently to document every notable VC transaction. VC investment data records reported here come from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs